Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Bayard L. Powell"'
Autor:
Bayard L. Powell, Kieron Dunleavy, Michelle A. Fanale, Philip J. Bierman, David Peace, Andrea Nicole Lucas, Jeremy S. Abramson, Wyndham H. Wilson, Christopher Melani, Stefania Pittaluga, Peter R. Watson, Seth M. Steinberg, Wahid Hanna, Brad S. Kahl, Elaine S. Jaffe, Mark Roschewski, Brian K. Link, Nancy L. Bartlett, Richard F. Little, Ariela Noy, Deepa Jagadeesh, Jonathan W. Friedberg, Prapti A. Patel, Ronald T. Mitsuyasu
Publikováno v:
J Clin Oncol
PURPOSE Burkitt lymphoma is an aggressive B-cell lymphoma curable with dose-intensive chemotherapy derived from pediatric leukemia regimens. Treatment is acutely toxic with late sequelae. We hypothesized that dose-adjusted etoposide, doxorubicin, cyc
Autor:
R.L. Bayer, Jerald P. Radich, Maria Brown, M. Lynn Savoie, Bruno C. Medeiros, Harry P. Erba, John M. Pagel, Selina M. Luger, Stephen A. Strickland, Sanjay R. Mohan, Guillermo Garcia-Manero, Dennis L. Confer, David A. Rizzieri, Stephen R. Spellman, Richard Stone, Geoffrey L. Uy, David F. Claxton, Mark R. Litzow, Min Fang, Frederick R. Appelbaum, Megan Othus, Mikkael A. Sekeres, Jeffrey Chell, Bayard L. Powell, James Essell, Guido Marcucci, Anna Moseley, Richard A. Larson, Tara L. Lin
Publikováno v:
JCO Oncol Pract
PURPOSE: Patients with acute myeloid leukemia with high-risk cytogenetics in first complete remission (CR1) achieve better outcomes if they undergo allogeneic hematopoietic cell transplantation (HCT) compared with consolidation chemotherapy alone. Ho
Autor:
Robert Morrell, Olivia M. Riffle, Gregory B. Russell, Katharine E. Duckworth, Richard P. McQuellon, Mollie Rose Canzona, Stephanie Lichiello, Bayard L. Powell, Aimee Tolbert
Publikováno v:
J Oncol Pract
PURPOSE: Adequate understanding of the goals and adverse effects of cancer treatment has important implications for patients’ decision making, expectations, and mood. This study sought to identify the degree to which patients and clinicians agreed
Autor:
Wendy Demark-Wahnefried, Stephen B. Kritchevsky, Shannon L. Mihalko, Bayard L. Powell, Leslie R. Ellis, Jack Rejeski, Timothy S. Pardee, Heidi D. Klepin, Ann M. Geiger, Janet A. Tooze, Dianna S. Howard
Publikováno v:
Journal of Clinical Oncology. 39:12009-12009
12009 Background: Older adults are at risk for physical function decline during therapy for AML. Impaired physical function after induction therapy is associated with shorter survival Interventions designed to maintain function may improve treatment
Autor:
Jun Ho Jang, Miklos Egyed, Martin S. Tallman, Ante Sven Lundberg, Richard Stone, Donna Neuberg, Dominik Selleslag, Harry P. Erba, Robert K. Stuart, Emanuele Mazzola, Lloyd E. Damon, Parameswaran Venugopal, Tamas Masszi, David A. Rizzieri, Mikkael A. Sekeres, Meir Wetzler, Heinz A. Horst, Steven L. Allen, Bayard L. Powell, Arnaud Pigneux, Krzysztof Warzocha, Scott R. Solomon
Publikováno v:
Journal of Clinical Oncology. 33:1252-1257
Purpose Secondary acute myeloid leukemia (sAML), defined as AML arising after a prior myelodysplastic syndrome or after antineoplastic therapy, responds poorly to current therapies. It is often associated with adverse karyotypic abnormalities and ove
Autor:
Philip C. Amrein, William Blum, Peter M. Voorhees, Daniel J. DeAngelo, Martha Wadleigh, Eyal C. Attar, Richard Stone, Clara D. Bloomfield, Jonathan E. Kolitz, Bayard L. Powell, Guido Marcucci, Jeffrey L. Johnson, Richard A. Larson, Barry K. Moser, Gerard Lozanski, Eunice S. Wang
Publikováno v:
Journal of Clinical Oncology. 31:923-929
Purpose The purpose of this study was to determine remission induction frequency when bortezomib was combined with daunorubicin and cytarabine in previously untreated older adults with acute myeloid leukemia (AML) and safety of bortezomib in combinat
Autor:
Michael D. Radmacher, Sebastian Schwind, Kati Maharry, Susan P. Whitman, Klaus H. Metzeler, Joseph O. Moore, Richard A. Larson, Deedra Nicolet, Meir Wetzler, Andrew J. Carroll, Heiko Becker, Krzysztof Mrózek, Jihane Khalife, Michael A. Caligiuri, Jessica Kohlschmidt, Maria R. Baer, Jonathan E. Kolitz, Bayard L. Powell, Guido Marcucci, Jason H. Mendler, Thomas H. Carter, Clara D. Bloomfield
Publikováno v:
Journal of Clinical Oncology. 30:3109-3118
Purpose To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures. Patients and Methods Youn
Autor:
Meir Wetzler, John Curfman, Michael A. Caligiuri, Heiko Becker, Sebastian Schwind, Klaus H. Metzeler, Joseph O. Moore, Dean Margeson, Richard A. Larson, Kati Maharry, Susan P. Whitman, Thomas H. Carter, Maria R. Baer, William Blum, Andrew J. Carroll, Yue-Zhong Wu, Jonathan E. Kolitz, Bayard L. Powell, Kelsi B. Holland, Clara D. Bloomfield, Michael D. Radmacher, Krzysztof Mrózek, Guido Marcucci
Publikováno v:
Journal of Clinical Oncology. 29:1373-1381
Purpose To determine the frequency of TET2 mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene- and microRNA-expression signatures in patients with primary cytogenetically normal acute myeloi
Autor:
Kati Maharry, Michael D. Radmacher, Claudia D. Baldus, Kelsi B. Holland, Krzysztof Mrózek, Klaus H. Metzeler, Richard A. Larson, Heiko Becker, Peter Paschka, Andrew J. Carroll, Sebastian Schwind, Dean Margeson, Christopher Hickey, Bayard L. Powell, Susan P. Whitman, Clara D. Bloomfield, Jonathan E. Kolitz, Michael A. Caligiuri, Ramiro Garzon, Guido Marcucci, Shujun Liu
Publikováno v:
Journal of Clinical Oncology. 28:5257-5264
Purpose To evaluate the prognostic significance of expression levels of a single microRNA, miR-181a, in the context of established molecular markers in cytogenetically normal acute myeloid leukemia (CN-AML), and to gain insight into the leukemogenic
Autor:
Paz Vellanki, Susan Lyerly, Leslie R. Ellis, Timothy S. Pardee, Sarah Dralle, Kavya Kannan, Heidi D. Klepin, Allison Winter, Bayard L. Powell, Bernard Tawfik, Dianna S. Howard, Megan Manuel, Scott Isom, Rupali Bhave
Publikováno v:
Journal of Clinical Oncology. 36:7021-7021
7021Background: Decision on re-induction (RI) therapy in adult patients with newly diagnosed acute myeloid leukemia (AML) who have received induction chemotherapy (ICT) when there are less than 20%...